For instance, Yao et al. (2021) have studied the biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells proposing that dual targeting mTOR and HDAC inhibitors is a promising strategy for triple negative breast cancer (TNBC) treatment. This evidence concerns the gene MTOR and triple-negative breast carcinoma.